The tweet was deleted by the author.
But we saved everything 🙂.
Summit Therapeutics issued an update on its Ivonescimab Biologics License Application. The stock is down 6.1% on the day at $14.15.
Summit Therapeutics provided an update on the regulatory status of its Ivonescimab Biologics License Application. The information appeared in a post from SMMT_TX, an account not affiliated with the company. The FDA is expected to decide on the application for Ivonescimab on November 14, 2026, according to Tech Times.
View post on X Loading...
Stoch RSI is in oversold territory, suggesting downside is limited and conditions may favor stabilization. The chart shows a significant move lower with price remaining below its MA-20, MA-50, and MA-200, reinforcing the bearish daily structure. The nearest support is the weekly low at $14.06, with no clear sign of a reversal yet at this level.
Traders should watch whether shares of Summit Therapeutics close above $15.76 or fall below $14.06 in the coming sessions. Right now, Stoch RSI remains in an oversold state, highlighting that further declines may be increasingly constrained. The recent move was sharp to the downside over the past week without a sustained trend; still, looking ahead over the next five trading days, the upside probability is less than 20% and the downside more than 80%, with an expected trading range of $12.32 to $15.97. A close above $15.76 would indicate buyers are returning, while a drop below $14.06 would confirm the move is being faded. On the weekly chart the longer-term picture stays firmly negative.
Earlier, analysts noted that Summit Therapeutics was under technical pressure despite a previously bullish trend structure. The recent regulatory update and further decline in share price underscore a firmly negative outlook, with traders advised to monitor the $14.06 support as a key downside risk in the days ahead.